Affymetrix Inc., of Santa Clara, Calif., and Stanford University, of Palo Alto, Calif., entered into an AcademicAccess agreement, where Stanford's researchers will gain access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software to monitor gene expression.

BioCryst Pharmaceuticals Inc., of Birmingham, Ala., received a $2 million milestone from Ortho-McNeil Pharmaceutical Inc., a division of Johnson & Johnson, of New Brunswick, N.J., in connection with the initiation of Phase II testing in the U.S. of an oral influenza neuraminidase inhibitor designed to treat and prevent viral influenza. The milestone came as part of its agreement with Ortho-McNeil and the R.W. Johnson Pharmaceutical Research Institute, both of Raritan, N.J.

Endorex Corp., of Chicago, presented data showing Orasome, a stable liposome delivery system, promotes the oral bioavailability of several hormone polypeptide therapeutics, insulin and human growth hormone. It said results confirm and extend earlier observations.

GlycoDesign, of Toronto, is expanding its Phase II trial of GD0039 in patients with renal cell carcinoma and colorectal cancer resistant to 5-FU, by adding a third site, the Jewish General Hospital in Montreal. It also is working with an investigator there to develop a protocol for the study of head and neck cancer.

ProQuest Investments, of Princeton, N.J., said it closed funding for an oncology-focused venture capital fund with $100 million in committed capital. The partnership is sponsored by Domain Associates. It will invest between $500,000 and $10 million per deal in pharmaceutical, device, discovery, delivery and other companies working in the area of cancer.

Inex Pharmaceuticals Corp., of Vancouver, British Columbia, closed on the second tranche of its previously announced $12 million offering. (See BioWorld Today, June 1, 1999, p. 1.)

Selectus Pharmaceuticals Inc., of West Conshohocken, Pa., is enrolling patients in a double-blind, placebo-controlled Phase IIb trial to evaluate the efficacy of esprolol for treating angina pectoris. Esprolol is a rapid-acting, sublingual beta-blocker. The trial is expected to be completed this fall.